We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
RVTY posted Q3 EPS of $1.18, beating estimates by 3.5%, on revenues of $698.9M, up 2.2% year over year.
RVTY's Diagnostics grew 3%, while Life Sciences was flat organically amid a 220-bps margin contraction.
RVTY raises 2025 EPS view to $4.90-$5.00, reflecting steady demand and stronger operational execution.
Revvity, Inc. (RVTY - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.18, which beat the Zacks Consensus Estimate of $1.14 by 3.5%. The bottom line, however, declined 7.8% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 40 cents compared with 77 cents in the prior-year period.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $698.9 million, up 2.2% year over year and 1% organically. The top line was almost in line with the Zacks Consensus Estimate.
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $343 million, flat organically year over year.
Adjusted operating income amounted to $101 million, down 9% from the prior-year quarter’s figure.
Diagnostics
This segment’s revenues totaled $345 million, up 3% on a year-over-year basis. Organically, the top line increased 2% year over year.
Adjusted operating income amounted to $89 million, down 5.3% from the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $241.9 million, up 1.8% year over year. Research and development expenses amounted to $50.8 million, up 3.4% from the year-ago quarter’s reported number.
Adjusted operating income declined 5.7% to $182.4 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 26.1%, contracting 220 basis points.
Financial Update
The company exited the third quarter of 2025 with cash and cash equivalents of $931.4 million compared with $991.8 million at the end of the prior quarter.
Net cash provided by operating activities totaled $138.9 million compared with $157 million in the year-ago quarter.
2025 Guidance
Revvity has raised its earnings outlook and updated its revenue guidance for 2025.
The company expects adjusted EPS to be in the range of $4.90-$5.00 (up from the earlier guidance of $4.85-$4.95). Revenues are now anticipated to be in the band of $2.83-$2.88 billion (previously $2.84-$2.88 billion). The Zacks Consensus Estimate for EPS and revenues is pegged at $4.87 and $2.85 billion, respectively.
Our Take
Revvity exited the third-quarter of 2025 on mixed note, wherein earnings beat estimates but sales were in line. Meanwhile, sales were up year over year but earnings declined. The company updated its revenue outlook to reflect recent currency movement as well as organic growth. The projection reflects growth of 2-4% organically.
Shares of RVTY were down 3.9% during pre-market trading following the mixed earnings result. The company’s shares have lost 11.4% so far this year against the industry’s growth of 6.1%.
Image Source: Zacks Investment Research
Revvity’s balanced performance across Life Sciences and Diagnostics reflects its ability to execute effectively while advancing innovation and expanding partnerships. Despite margin pressures, operational discipline and portfolio focus continue to support profitability and cash generation. Management’s reaffirmation of full-year organic growth and upward revision of adjusted earnings guidance demonstrate confidence in the company’s trajectory and underlying demand drivers.
The newly authorized $1 billion share repurchase program highlights a strong balance sheet and ongoing commitment to shareholder returns. With new product launches gaining traction and strategic initiatives beginning to yield results, Revvity appears well-positioned to strengthen its market position heading into 2026. Overall, the quarter reinforces the company’s long-term strategy of driving sustainable growth through innovation, operational efficiency, and disciplined capital allocation.
RVTY’s Zacks Rank & Stocks to Consider
RVTY has a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , HealthEquity (HQY - Free Report) and Solventum Corporation (SOLV - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 13.2% compared with the industry’s 5.6% growth so far this year.
HealthEquity, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.7%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 11.05%.
HealthEquity’s shares have increased 0.6% compared with the industry’s 6.2% growth so far this year.
Solventum, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 4.1%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%.
Solventum’s shares have gained 8.2% compared with the industry’s 6.2% growth so far this year.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
RVTY Q3 Earnings Beat, Sales In Line, '25 EPS View Raised
Key Takeaways
Revvity, Inc. (RVTY - Free Report) reported third-quarter 2025 adjusted earnings per share (EPS) of $1.18, which beat the Zacks Consensus Estimate of $1.14 by 3.5%. The bottom line, however, declined 7.8% from the year-ago quarter’s level.
GAAP EPS from continuing operations was 40 cents compared with 77 cents in the prior-year period.
Revenue Details
Based in Waltham, MA, this leading MedTech company reported revenues of $698.9 million, up 2.2% year over year and 1% organically. The top line was almost in line with the Zacks Consensus Estimate.
Revvity Inc. Price, Consensus and EPS Surprise
Revvity Inc. price-consensus-eps-surprise-chart | Revvity Inc. Quote
Segmental Details
Revvity reports under two operating segments — Life Sciences and Diagnostics.
Life Sciences
Revenues from this segment totaled $343 million, flat organically year over year.
Adjusted operating income amounted to $101 million, down 9% from the prior-year quarter’s figure.
Diagnostics
This segment’s revenues totaled $345 million, up 3% on a year-over-year basis. Organically, the top line increased 2% year over year.
Adjusted operating income amounted to $89 million, down 5.3% from the year-ago quarter’s figure.
Margin Analysis
Selling, general and administrative expenses totaled $241.9 million, up 1.8% year over year. Research and development expenses amounted to $50.8 million, up 3.4% from the year-ago quarter’s reported number.
Adjusted operating income declined 5.7% to $182.4 million from the year-ago quarter’s level. Adjusted operating margin, as a percentage of revenues, was 26.1%, contracting 220 basis points.
Financial Update
The company exited the third quarter of 2025 with cash and cash equivalents of $931.4 million compared with $991.8 million at the end of the prior quarter.
Net cash provided by operating activities totaled $138.9 million compared with $157 million in the year-ago quarter.
2025 Guidance
Revvity has raised its earnings outlook and updated its revenue guidance for 2025.
The company expects adjusted EPS to be in the range of $4.90-$5.00 (up from the earlier guidance of $4.85-$4.95). Revenues are now anticipated to be in the band of $2.83-$2.88 billion (previously $2.84-$2.88 billion). The Zacks Consensus Estimate for EPS and revenues is pegged at $4.87 and $2.85 billion, respectively.
Our Take
Revvity exited the third-quarter of 2025 on mixed note, wherein earnings beat estimates but sales were in line. Meanwhile, sales were up year over year but earnings declined. The company updated its revenue outlook to reflect recent currency movement as well as organic growth. The projection reflects growth of 2-4% organically.
Shares of RVTY were down 3.9% during pre-market trading following the mixed earnings result. The company’s shares have lost 11.4% so far this year against the industry’s growth of 6.1%.
Image Source: Zacks Investment Research
Revvity’s balanced performance across Life Sciences and Diagnostics reflects its ability to execute effectively while advancing innovation and expanding partnerships. Despite margin pressures, operational discipline and portfolio focus continue to support profitability and cash generation. Management’s reaffirmation of full-year organic growth and upward revision of adjusted earnings guidance demonstrate confidence in the company’s trajectory and underlying demand drivers.
The newly authorized $1 billion share repurchase program highlights a strong balance sheet and ongoing commitment to shareholder returns. With new product launches gaining traction and strategic initiatives beginning to yield results, Revvity appears well-positioned to strengthen its market position heading into 2026. Overall, the quarter reinforces the company’s long-term strategy of driving sustainable growth through innovation, operational efficiency, and disciplined capital allocation.
RVTY’s Zacks Rank & Stocks to Consider
RVTY has a Zacks Rank #4 (Sell) at present.
Some better-ranked stocks in the broader medical space are Boston Scientific Corporation (BSX - Free Report) , HealthEquity (HQY - Free Report) and Solventum Corporation (SOLV - Free Report) .
Boston Scientific, carrying a Zacks Rank #2 (Buy) at present, has an estimated long-term growth rate of 14%. BSX’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 8.1%. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Boston Scientific’s shares have gained 13.2% compared with the industry’s 5.6% growth so far this year.
HealthEquity, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 21.7%. HQY’s earnings surpassed estimates in three of the trailing four quarters and missed once, with the average surprise being 11.05%.
HealthEquity’s shares have increased 0.6% compared with the industry’s 6.2% growth so far this year.
Solventum, carrying a Zacks Rank of 2 at present, has an estimated long-term growth rate of 4.1%. SOLV’s earnings surpassed estimates in each of the trailing four quarters, with the average surprise being 13.91%.
Solventum’s shares have gained 8.2% compared with the industry’s 6.2% growth so far this year.